Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Zhuhai Tengbai Pharmaceutical Co. Ltd. is currently prosecuting 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to a distinct examiner and is located within 1 distinct art unit. This concentration suggests a highly specialized technical focus for the company's current patenting efforts. This concentration allows for a streamlined approach to patent strategy, as the applicant only needs to navigate the specific requirements of the involved administrative unit.
The busiest examiner for this portfolio is LEE, JIA-HAI. This examiner is currently handling 1 busiest examiner pending office action. As the total number of pending actions is limited, this examiner is the sole official reviewing the company's active applications. The presence of 1 distinct art unit simplifies the prosecution landscape, allowing the applicant to focus on the specific examination trends of that unit. Practitioners should focus on the individual examination style of the assigned official to navigate the prosecution process effectively. The lack of multiple pending matters simplifies the management of the portfolio but increases the importance of the outcome for this specific case in the biotechnology field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, JIA-HAI | 1 | 49.0% | +46.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18598527 | POLYPEPTIDE DRUG FOR PREVENTING AND/OR TREATING NEUROBLASTOMA AND USE THEREOF | LEE, JIA-HAI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18598527 | POLYPEPTIDE DRUG FOR PREVENTING AND/OR TREATING NEUROBLASTOMA AND USE THEREOF | LEE, JIA-HAI | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18598527 | POLYPEPTIDE DRUG FOR PREVENTING AND/OR TREATING NEUROBLASTOMA AND USE THEREOF | LEE, JIA-HAI | 1658 | §103§112 | Non-Final OA | — | Pending | Mar 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZhuhai Tengbai Pharmaceutical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jia-Hai Lee has the most, with 1 of Zhuhai Tengbai Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
